EA200900795A1 - Вакцина - Google Patents

Вакцина

Info

Publication number
EA200900795A1
EA200900795A1 EA200900795A EA200900795A EA200900795A1 EA 200900795 A1 EA200900795 A1 EA 200900795A1 EA 200900795 A EA200900795 A EA 200900795A EA 200900795 A EA200900795 A EA 200900795A EA 200900795 A1 EA200900795 A1 EA 200900795A1
Authority
EA
Eurasian Patent Office
Prior art keywords
preparation
proteins containing
protein
fusion partner
antigen
Prior art date
Application number
EA200900795A
Other languages
English (en)
Other versions
EA016326B1 (ru
Inventor
Норман Блэйс
Денис Мартин
Реми М. Палмантье
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39300029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200900795(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0700760A external-priority patent/GB0700760D0/en
Priority claimed from GB0701262A external-priority patent/GB0701262D0/en
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA200900795A1 publication Critical patent/EA200900795A1/ru
Publication of EA016326B1 publication Critical patent/EA016326B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к слитым белкам, содержащим антиген, имеющий происхождение от так называемого антигена отторжения опухоли PRAME (также известного как DAGE), связанный с иммунологическим партнером слияния, который дает эпитопы Т-хелперов, таким как, например, белок D из Haemophilus influenzae В, к белкам-партнерам слияния, содержащим фрагменты белка D, к способам их получения и приготовления вакцин, и к их применению для лечения целого ряда раковых заболеваний.
EA200900795A 2007-01-15 2008-01-11 Вакцина EA016326B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0700760A GB0700760D0 (en) 2007-01-15 2007-01-15 Vaccine
GB0701262A GB0701262D0 (en) 2007-01-23 2007-01-23 Vaccine
PCT/EP2008/050290 WO2008087102A1 (en) 2007-01-15 2008-01-11 Vaccine

Publications (2)

Publication Number Publication Date
EA200900795A1 true EA200900795A1 (ru) 2010-02-26
EA016326B1 EA016326B1 (ru) 2012-04-30

Family

ID=39300029

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900795A EA016326B1 (ru) 2007-01-15 2008-01-11 Вакцина

Country Status (32)

Country Link
US (1) US20080187535A1 (ru)
EP (1) EP2114993B1 (ru)
JP (1) JP5391080B2 (ru)
KR (1) KR20090101313A (ru)
CN (1) CN101668770B (ru)
AR (1) AR064862A1 (ru)
AU (1) AU2008207025B2 (ru)
BR (1) BRPI0806463A2 (ru)
CA (1) CA2674552A1 (ru)
CL (1) CL2008000104A1 (ru)
CO (1) CO6210757A2 (ru)
CR (1) CR10971A (ru)
CY (1) CY1113760T1 (ru)
DK (1) DK2114993T3 (ru)
DO (1) DOP2009000167A (ru)
EA (1) EA016326B1 (ru)
ES (1) ES2393812T3 (ru)
HK (1) HK1138853A1 (ru)
HR (1) HRP20120828T1 (ru)
IL (1) IL199663A0 (ru)
JO (1) JO2840B1 (ru)
MA (1) MA31093B1 (ru)
MX (1) MX2009007571A (ru)
MY (1) MY153679A (ru)
NZ (1) NZ578285A (ru)
PE (2) PE20130324A1 (ru)
PL (1) PL2114993T3 (ru)
PT (1) PT2114993E (ru)
SI (1) SI2114993T1 (ru)
TW (1) TWI434697B (ru)
WO (1) WO2008087102A1 (ru)
ZA (1) ZA200904923B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200902049A (en) * 2007-01-15 2009-01-16 Glaxosmithkline Biolog Sa Fusion protein
BRPI1009873A2 (pt) 2009-03-17 2016-03-08 Glaxosmithkline Biolog Sa detecção aperfeiçoada de expressão gênica
EP2438173A4 (en) * 2009-06-05 2012-10-31 Univ Ohio State Res Found BIOMATERIALS, COMPOSITIONS AND METHODS
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008682D0 (en) * 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
EP2734539A1 (en) * 2011-07-22 2014-05-28 GlaxoSmithKline Biologicals S.A. Prame purification
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
RU2590701C2 (ru) * 2013-04-29 2016-07-10 Общество с ограниченной ответственностью "ГеноТехнология" Антигенная композиция и ее терапевтическое применение для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, а также способ получения белка
EP3053592A4 (en) 2013-10-01 2017-09-06 Mie University T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
CN105254767A (zh) * 2015-11-17 2016-01-20 重庆科润生物医药研发有限公司 一种Protein D与HER2融合蛋白及其制备方法和应用
WO2018102584A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别源自于prame抗原短肽的tcr
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr及其相关组合物
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
WO2019094607A2 (en) * 2017-11-08 2019-05-16 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
CN109879957B (zh) * 2017-12-06 2022-03-18 香雪生命科学技术（广东）有限公司 针对prame的高亲和力t细胞受体
US20230190902A1 (en) * 2020-05-29 2023-06-22 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
AU1217395A (en) * 1993-12-23 1995-07-10 GFF Gesellschaft zur Forderung der industrie-orientierten Forschung Immunological response potentiation process
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1584685B1 (en) 1998-02-05 2011-04-13 GlaxoSmithKline Biologicals SA Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination
CA2363118A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
EP1198249B1 (en) * 1999-06-29 2005-10-19 GlaxoSmithKline Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
AU5926700A (en) * 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro

Also Published As

Publication number Publication date
CO6210757A2 (es) 2010-10-20
CN101668770A (zh) 2010-03-10
MX2009007571A (es) 2009-07-22
IL199663A0 (en) 2010-04-15
HK1138853A1 (en) 2010-09-03
EP2114993A1 (en) 2009-11-11
EP2114993B1 (en) 2012-08-29
CL2008000104A1 (es) 2008-07-18
CR10971A (es) 2009-09-09
AR064862A1 (es) 2009-04-29
KR20090101313A (ko) 2009-09-24
TW200902048A (en) 2009-01-16
DK2114993T3 (da) 2012-10-22
WO2008087102A1 (en) 2008-07-24
AU2008207025A1 (en) 2008-07-24
PE20081686A1 (es) 2008-12-25
NZ578285A (en) 2011-12-22
ZA200904923B (en) 2012-12-27
JO2840B1 (en) 2014-09-15
EA016326B1 (ru) 2012-04-30
PE20130324A1 (es) 2013-03-05
CN101668770B (zh) 2013-06-12
MA31093B1 (fr) 2010-01-04
SI2114993T1 (sl) 2012-12-31
PT2114993E (pt) 2012-11-28
CY1113760T1 (el) 2016-07-27
JP2010515444A (ja) 2010-05-13
DOP2009000167A (es) 2009-07-15
MY153679A (en) 2015-03-13
BRPI0806463A2 (pt) 2011-09-06
JP5391080B2 (ja) 2014-01-15
CA2674552A1 (en) 2008-07-24
ES2393812T3 (es) 2012-12-28
TWI434697B (zh) 2014-04-21
HRP20120828T1 (hr) 2012-11-30
AU2008207025B2 (en) 2012-08-23
US20080187535A1 (en) 2008-08-07
PL2114993T3 (pl) 2013-01-31

Similar Documents

Publication Publication Date Title
EA200900795A1 (ru) Вакцина
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
EA202190587A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
PH12018502348A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
EA201892793A1 (ru) Анти-hla-g специфические антитела
EA201992664A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
EA202191027A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
BR112014011229A2 (pt) composições e métodos para o tratamento de citomegalovírus
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
UA114108C2 (uk) Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
MX2022007902A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
MX2020005188A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
EA202190241A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии хлл и других видов рака
EA202091878A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
EA202190465A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака
EA202092502A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов рака
EA202191013A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии и способы получения каркасов для применения при лечении рака поджелудочной железы и других видов рака
TH126648A (th) Ect2 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น
TH114418B (th) วัคซีน
TH126648B (th) Ect2 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น
PL401359A1 (pl) Przeciwciala poliklonalne klasy IgY specyficzne wobec bialka gp120 wirusa HIV-1, sposób ich wytwarzania oraz ich zastosowanie

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU